glp 1 intestine A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism: Cell Metabolism Pancreas and Not Gut Mediates
Description
Is it possible to summarize the outcomes of that trial?

There are no large trials proving safety, but early data suggests milk transfer is low

No, a pre-diabetic individual should not routinely take both metformin and a GLP-1 receptor agonist together, as current guidelines recommend against using G...

Treatment guidelines focus on nutrition, exercise, and pharmacologic therapies to prevent and manage complications

Secondary outcomes generated similar results but with wider confidence intervals

Retatrutide, a novel triple GLP-1/GIP/glucagon receptor agonist, typically shows measurable metabolic changes within 24 weeks, with weight loss acceleration by 812 weeks
